当前的癌症临床试验

Prospective, Randomized, Crossover Trial Comparing Recombinant Von Willebrand Factor (rVWF) vs. Tranexamic Acid (TA) to Minimize Menorrhagia in Women With Type 1 Von Willebrand Disease: The VWD Minimize Study（（NCT02606045）
主要我nvestigator: Dr. Danielle Nance

Observational Study Evaluating Effectiveness and Safety of Real-World Treatment With Damoctocog Alfa Pegol in Previously Treated Patients With Hemophilia A（（NCT03932201）
主要我nvestigator: Danielle Nance

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia（（NCT03764618）
主要我nvestigator: Michael Stanek

Bladder Cancer

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors（（NCT03170960）
主要我nvestigator: Dr. Jiaxin Niu

RP1作为单一药物的开放标签，多中心，1/2阶段研究，与实体瘤患者的PD1阻滞结合（（NCT03767348）
主要我nvestigator: Dr. Jiaxin Niu

一项III期随机试验，以评估BCG菌株差异和T细胞启动在内内内BCG之前对BCG-无肌肉的非肌肉非肌肉浸润性膀胱癌的影响（（NCT03091660）
主要我nvestigator: Chinedu Mmeje

一项III期随机试验，以评估BCG菌株差异和T细胞启动在内内内BCG之前对BCG-无肌肉的非肌肉非肌肉浸润性膀胱癌的影响（（NCT03091660）
主要我nvestigator: Chinedu Mmeje

Prostate Cancer

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors（（NCT03170960）
主要我nvestigator: Dr. Jiaxin Niu

Solid Tumor

A Phase 1b/2 Study of FT-2102 in Patients with Advanced Solid Tumors and Gliomas with an IDH1 Mutation（（NCT03684811）
首席研究员：Madappa Kundranda博士

A Phase 2 Study of Olaparib in Combination With Pembrolizumab in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer（（NCT04123366）
主要研究人员：LIDA MINA

A Phase 1 Study Evaluating the Safety and Efficacy of HPV16 E7 T Cell（（NCT03912831）
主要我nvestigator: Jiaxin Niu

阶段1 / 2的多中心研究安全、制药acokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors（（NCT03175224）
主要我nvestigator: Jiaxin Niu

BYLieve: A Phase II, Multicenter, Open-label, Three-cohort, Non- Comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After Prior Treatments（（NCT03056755）
主要我nvestigator: Shakeela Bahadur

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/=1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy（（NCT02954874）
主要我nvestigator: Shakeela Bahadur

Tucatinib或安慰剂与Ado-Trastuzumab Emtansine（T-DM1）的随机，双盲，第3阶段研究，针对患有无法切除的局部增长或转移性HER2+乳腺癌的受试者（HER2CLIMB-02）（（NCT03975647）
主要研究人员：LIDA MINA

A Phase 1/2, Open-Label, Dose-Escalation Study of ISB 1302 in Subjects With HER2-Positive Metastatic Breast Cancer（（NCT03983395）
主要研究人员：LIDA MINA

A Phase 1 Study of BOS172738 in Patients With Advanced Solid Tumors With RET Gene Alterations Including Non-Small Cell Lung Cancer (NSCLC) and Medullary Thyroid Cancer (MTC)（（NCT03780517）
主要我nvestigator: Jiaxin Niu

A Phase 2 Study of Olaparib in Combination With Pembrolizumab in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer（（NCT04123366）
主要研究人员：LIDA MINA

阶段1 / 2的多中心研究安全、制药acokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors（（NCT03175224）
主要我nvestigator: Jiaxin Niu

Multicenter Trial for Eliminating Breast Cancer Surgery in Exceptional Responders With Neoadjuvant Systemic Therapy（（NCT02945579）
主要我nvestigator: Stephanie Byrum

Optimizing Preventative Adjuvant Linac-Based Radiation: The OPAL Trial a Phase II/III Study of Hypofractionated Partial Breast Irradiation in Women With Early Stage Breast Cancer（（NCT03077841）
主要我nvestigator: Mohammed Khan

Prospective Registry of Breast Cancer Patients with Axillary Nodal Metastases Identified During
主要我nvestigator: Stephanie Byrum

Prospective Registry of Women Who are at Increased risk for Developing Breast Cancer
主要研究人员：LIDA MINA

乳房中心基因测试研究方案通用遗传性遗传性癌症面板测试针对乳腺癌女性
主要研究人员：LIDA MINA

A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study of DS-8201a, an Anti-HER2-antibody Drug Conjugate, Versus Treatment of Investigator's Choice for HER2-positive, Unresectable and/or Metastatic Breast Cancer Subjects Pretreated With Prior Standard of Care HER2 Therapies, Including T-DM1（（NCT03523585）
首席研究员：LIDA Mina博士

三阴性乳腺癌患者的Zen003694与Talazoparib结合的2阶段研究（（NCT03901469）
首席研究员：LIDA Mina博士

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and在新辅助化学疗法之前，在新辅助化学疗法后转化为病理性腋窝淋巴结前阳性腋窝淋巴结阳性的患者的区域淋巴结XRT和倾斜后切除术区域淋巴结XRT（（NCT01872975）
主要我nvestigator: Dr. Emily Grade

Phase 1/1b Multicenter, Open-Label, First-in-Human Dose Escalation and Dose Expansion Study to Assess Safety and Tolerability of Orally Administered PMD-026 in Patients with Metastatic Breast Cancer with Expansion in Metastatic Triple Negative Breast Cancer（（NCT04115306）
首席研究员：LIDA Mina博士

A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of T3011 in Advanced Cutaneous or Subcutaneous Malignancies（（NCT04370587）
主要我nvestigator: Jiaxin Niu

Biliary Cancer

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib Versus Gemcitabine With Cisplatin in Subjects With Advanced/Metastatic or Inoperable Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations: The PROOF Trial（（NCT03773302）
首席研究员：Madappa Kundranda博士

Xermelo®（Telotristat Ethyl）的第二阶段，多中心，开放标签，安全性和功效研究以及局部晚期，无法切除，反复发生或转移性胆道癌（BTC）的患者的一线化学疗法（BTC）（（NCT03790111）
首席研究员：鲍里斯·纳拉维夫（Boris Naraev）

A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp alfa (M7824) as First-line Treatment of Biliary Tract Cancer（（NCT04066491）
主要我nvestigator: Madappa Kundranda

Colorectal Cancer

一项随机、多中心、与这些相应平行的组织,第一阶段II study to compare the efficacy of arfolitixorin versus leucovorin in combination with 5-fluorouracil, oxaliplatin, and bevacizumab in patients with advanced colorectal cancer（（NCT03750786）
首席研究员：Madappa Kundranda博士

主要我nvestigator: Dr. Tomislav Dragovich

直肠癌中使用全新辅助治疗（TNT）的敏化敏化平台的II期临床试验平台（（NCT02921256)
主要我nvestigator: Dr.Gary Walker

Phase 1, Two-part (Dose Escalation, Dose Expansion), Multicenter, Non-randomized, Open-label, Multiple Dose, First-in-human Study of CA102N Monotherapy and of CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors（NCT03616574）
主要我nvestigator: Dr. Tomislav Dragovich

Gastric/GEJ

Liver Cancer

A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937)（（NCT03867084）

主要我nvestigator: Madappa Kundranda

Neuroendocrine Tumor

A prospective, randomised, Controlled, Open-label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somato-statin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET).（（NCT03049189）
首席研究员：鲍里斯·纳拉维夫（Boris Naraev）

Pancreatic Cancer

与吉西他滨和NAB-甲状腺素有关的肿瘤治疗场（TTFIELDS，150KHz）的关键，随机，开放标签研究（TTFIELDS，150KHz），用于局部增强胰腺腺癌的前线治疗（（NCT03377491)
主要我nvestigator: Dr. Tomislav Dragovich

A Phase II Study Evaluating Bi-weekly Dosing of Gemcitabine Plus nab-Paclitaxel In The First Line Treatment Metastatic Pancreatic Cancer In Older Adults ( >70 years old)
主要我nvestigator: Madappa Kundranda

Solid Tumor

BOS172738对患有RET基因改变的患者的BOS172738研究，包括非小细胞肺癌（NSCLC）和甲状腺甲状腺癌（MTC）（（NCT03780517）
主要我nvestigator: Dr. Jiaxin Niu

RP1作为单一药物的开放标签，多中心，1/2阶段研究，与实体瘤患者的PD1阻滞结合（（NCT03767348）
主要我nvestigator: Dr. Jiaxin Niu

“ 1/2阶段1 /2对APL-101的安全性，药代动力学和初步疗效的多中心研究在具有C-MET外显子14跳过的非小细胞肺癌的受试者中，SKIP突变和C-MET c-MET失调晚期实体瘤”（（NCT03175224）
主要我nvestigator: Jiaxin Niu

"A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer"（（NCT04123366）
主要研究人员：LIDA MINA

BOS172738对患有RET基因改变的患者的BOS172738研究，包括非小细胞肺癌（NSCLC）和甲状腺甲状腺癌（MTC）（（NCT03780517）
主要我nvestigator: Jiaxin Niu

Cervical Cancer

单独使用FLX475并与pembrolizumab联合使用晚期癌症中的1/2阶段1/2剂量 - 定量和扩张研究（（NCT03674567）
首席研究员：Tomislav Dragovich

Solid Tumor

RP1作为单一药物的开放标签，多中心，1/2阶段研究，与实体瘤患者的PD1阻滞结合（（NCT03767348）
主要我nvestigator: Dr. Jiaxan Niu

阶段1 / 2的多中心研究安全、制药acokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors（（NCT03175224）
主要我nvestigator: Jiaxin Niu

A Phase 2 Study of Olaparib in Combination With Pembrolizumab in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer（（NCT04123366）
主要研究人员：LIDA MINA

A Phase 1 Study Evaluating the Safety and Efficacy of HPV16 E7 T Cell Receptor Engineered T Cells (KITE-439) in HLA-A*02:01+ Subjects with Relapsed/Refractory HPV16+ Cancers（（NCT03912831）
主要我nvestigator: Jiaxin Niu

A Phase I/II Study of HB-201 Monotherapy or in Combination with Nivolumab in Patients with Human Papillomavirus 16 Positive (HPV 16+) Confirmed Cancers
主要我nvestigator: Dr. Jiaxan Niu

RP1作为单一药物的开放标签，多中心，1/2阶段研究，与实体瘤患者的PD1阻滞结合（（NCT03767348)
主要我nvestigator: Dr. Jiaxin Niu

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors（（NCT03170960）
主要我nvestigator: Dr. Jiaxin Niu

A Phase I/II Study of NBTXR3 Activated by SABR for Patients With Advanced HNSCC or NSCLC Treated With an Anti-PD1 Antibody（（NCT03589339）
主要我nvestigator: Dr. Jiaxin Niu

单独使用FLX475并与pembrolizumab联合使用晚期癌症中的1/2阶段1/2剂量 - 定量和扩张研究（（NCT03674567）
首席研究员：Tomislav Dragovich

A Phase 1 Study Evaluating the Safety and Efficacy of HPV16 E7 T Cell Receptor Engineered T Cells (KITE-439) in HLA-A*02:01+ Subjects with Relapsed/Refractory HPV16+ Cancers（（NCT03912831）
主要我nvestigator: Dr. Jiaxin Niu

A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation versus Conventional Care in Older Subjects with Active, Relapsed or Refractory Acute Myeloid Leukemia（（NCT02665065)
主要我nvestigator: Dr. Rajneesh Nath

Phase III Randomized Trial of DFP-10917 vs. Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second or Third Salvage（（NCT02665065）
主要我nvestigator: Dr. Rajneesh Nath

对非小细胞肺癌（NSCLC）的受试者中的联合免疫疗法和mRNA疫苗的1/2期研究（（NCT03164772)
主要我nvestigator: Dr. Jiaxin Niu

A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671)（（NCT03425643)

主要我nvestigator: Dr. Qing Zhao

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors（（NCT03170960）
主要我nvestigator: Dr. Jiaxin Niu

A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer（（NCT02716116）
主要我nvestigator: Dr. Jiaxin Niu

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein binding PD-1 and LAG-3 in Patients with Unresectable or Metastatic Neoplasms（（NCT03219268）
主要我nvestigator: Shakeela Bahadur

单独使用FLX475并与pembrolizumab联合使用晚期癌症中的1/2阶段1/2剂量 - 定量和扩张研究（（NCT03674567）
首席研究员：Tomislav Dragovich

“ 1/2阶段1 /2对APL-101的安全性，药代动力学和初步疗效的多中心研究在具有C-MET外显子14跳过的非小细胞肺癌的受试者中，SKIP突变和C-MET c-MET失调晚期实体瘤”（（NCT03175224）
主要我nvestigator: Jiaxin Niu

BOS172738对患有RET基因改变的患者的BOS172738研究，包括非小细胞肺癌（NSCLC）和甲状腺甲状腺癌（MTC）（（NCT03780517）
主要我nvestigator: Dr. Jiaxin Niu

A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, as a Single Agent and as Combination Therapy in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies（（NCT02922764）
主要我nvestigator: Jiaxin Niu

阶段1 / 2的多中心研究安全、制药acokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors（（NCT03175224）
主要我nvestigator: Jiaxin Niu

RP1作为单一药物的开放标签，多中心，1/2阶段研究，与实体瘤患者的PD1阻滞结合（（NCT03767348）
主要我nvestigator: Dr. Jiaxin Niu

"A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer"（（NCT04123366）
主要研究人员：LIDA MINA

一项评估BDX-XL2测试性能的观察注册表研究（（NCT03766958）
主要我nvestigator: Dr. Archan Shah

A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006)（（NCT03483103)
主要我nvestigator: Rajneesh Nath (Please note: The study recruitment for this study are currently on hold)

A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)（NCT03105336）
主要我nvestigator: Matthew Ulrickson

IB/II期，开放标签，多中心，随机，对照研究，研究了Mosunetuzumab（BTCT4465A）与B-Cell非hod-Hodgkin淋巴瘤患者患者的安全性，耐受性，药代动力学和功效（（NCT03677141)
主要我nvestigator: Horst Klueppelberg

A SINGLE-ARM, OPEN-LABEL, PHASE 1/2 STUDY EVALUATING THE SAFETY, EFFICACY, AND CELLULAR KINETICS/PHARMACODYNAMICS OF ALLO-501, AN ANTI-CD19 ALLOGENEIC CAR T CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL AND FOLLICULAR LYMPHOMA（（NCT03939026）
主要我nvestigator: Rajneesh Nath

A Multicenter, Two Part, Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Subjects With Advanced Melanoma（（NCT03084640）
主要我nvestigator: Fade Mahmoud

RP1作为单一药物的开放标签，多中心，1/2阶段研究，与实体瘤患者的PD1阻滞结合（（NCT03767348）
主要我nvestigator: Dr. Jiaxan Niu

与Carfilzomib和Dexamethasone（DKD）相比，与Carfilzomib和Carfilzomib和Dexamethasone（KD）相比，Daratumumab皮下（DARA-SC）给药的2期研究与多发性骨髓瘤相比达拉特珠单抗撤退（（NCT03871829）
主要我nvestigator: Sumit Madan

Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P BCMA-101 in Subjects With Relapsed / Refractory Multiple Myeloma (MM) Followed by a Phase 2 Assessment of Response and Safety (PRIME)（（NCT03288493）
主要我nvestigator: Rajneesh Nath

A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients With Relapsed/Refractory Multiple Myeloma（（NCT03288493）
主要我nvestigator: Rajneesh Nath

一项多中心，开放标签的1B期研究，用于评估皮下和静脉内ISATUXIMAB（SAR650984）的药代动力学，安全性和功效，并在患有复发/抑制性多发性骨髓瘤（RRMM）的患者中与Pomalidomide和Texamethasone结合使用。（（NCT04045795）
主要我nvestigator: Sumit Madan

随访时间,非盲、Saf的第一阶段研究ety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-715 to Evaluate an Anti-BCMA Allogeneic CAR T Cell Therapy in Subjects With Relapsed/Refractory Multiple Myeloma（（NCT04093596）
主要我nvestigator: Rajneesh Nath

A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma and Newly Diagnosed Multiple Myeloma（（NCT02343042）
主要我nvestigator: Sumit Madan

A Phase 1, Open-Label, Multicenter, Dose Escalation, Dose Expansion Study of PRT543 in Patients With Advanced Solid Tumors and Hematologic Malignancies（（NCT03886831）
主要我nvestigator: Rajneesh Nath

Breast Cancer

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy（（NCT1872975)
主要我nvestigator: Dr.Emily Grade

Head and Neck Cancer

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Superoxide Dismutase Mimetic GC4419 to Reduce Severe Oral Mucositis (SOM) Associated with Chemoradiotherapy for Locally Advanced, Non-Metastatic Head and Neck Cancer（（NCT03689712)
主要我nvestigator: Dr.Gary Walker

Prostate Cancer

Prospective Data Registry and Quality of Life Assessment of Men Undergoing High Dose Rate Brachytherapy of the Prostate Using Real-Time Ultrasound Planning
主要我nvestigator: Dr. Anna Likhacheva

Rectal Cancer

直肠癌中使用全新辅助治疗（TNT）的敏化敏化平台的II期临床试验平台（（NCT02921256)
主要我nvestigator: Dr.Gary Walker

Skin Cancer

非黑色瘤皮肤癌的皮肤表面近距离治疗：前瞻性数据注册和生活质量评估
主要我nvestigator: Dr.Emily Grade

Solid Tumor

EXTernal beam radiation to Eliminate Nominal metastatic Disease (EXTEND): A randomized phase II basket trial assessing the efficacy of upfront local consolidative therapy (LCT) for oligometastatic disease（（NCT03599765)
主要我nvestigator: Dr.Gary Walker

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors（（NCT03170960）
主要我nvestigator: Jiaxin Niu

BOS172738对患有RET基因改变的患者的BOS172738研究，包括非小细胞肺癌（NSCLC）和甲状腺甲状腺癌（MTC）（（NCT03780517）
主要我nvestigator: Jiaxin Niu